MLchartDataset catalogue

Lazcluze

Term · Oncology and biomedicine · MLC-T-ONC-004753

A drug used with amivantamab to treat adults with non-small cell lung cancer that has spread to other parts of the body or cannot be removed by surgery and has certain mutations (changes) in the EGFR gene. Lazcluze blocks certain proteins made by the mutated EGFR gene, which may help keep cancer cells from growing and may kill them. It is a type of tyrosine kinase inhibitor. Also called lazertinib mesylate hydrate.

Table 1. Record
IdentifierMLC-T-ONC-004753
FieldOncology and biomedicine
Synonymslazertinib mesylate hydrate
ReferencesNCI Dictionary of Cancer Terms
Record as JSON
{
  "id": "MLC-T-ONC-004753",
  "term": "Lazcluze",
  "field": "Oncology and biomedicine",
  "definition": "A drug used with amivantamab to treat adults with non-small cell lung cancer that has spread to other parts of the body or cannot be removed by surgery and has certain mutations (changes) in the EGFR gene. Lazcluze blocks certain proteins made by the mutated EGFR gene, which may help keep cancer cells from growing and may kill them. It is a type of tyrosine kinase inhibitor. Also called lazertinib mesylate hydrate.",
  "synonyms": [
    "lazertinib mesylate hydrate"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/lazcluze/"
}

Record 9,968 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.